Inflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known as “cytokine storm”, it can cause harm to the patient. It has been thought that a cytokine storm contributes to disease severity in patients with COVID-19. Following the measurement of several important cytokines in patients with COVID-19 and various other severe diseases, researchers at Radboud university medical center now show that COVID-19 is not characterized by a cytokine storm. This may have consequences for the treatment of these patients, the researchers write in JAMA.
The cytokine storm in COVID-19 patients is not clearly defined. In many cases, different cytokines are evaluated and no comparison has been made with other diseases. Therefore, uncertainty and doubt exists concerning the cytokine storm in these patients.
Various patient groups
Researchers from the Intensive Care (IC) department at Radboud university medical center have now measured the concentration of three essential cytokines in the blood of patients admitted to the IC with several distinct conditions. They performed these measurements in patients with COVID-19 who met the criteria for a severe acute respiratory infection (ARDS), patients with bacterial septic shock (with and without ARDS), and patients who had been admitted to the IC after a cardiac arrest or severe trauma. The cytokines were measured using the same methods for each of the groups of patients.
In the abovedescribed five patient groups, the concentration of tumor necrosis factor alpha (TNF-alpha) and interleukins 6 and 8 (IL-6, IL-8) was measured. The results were remarkable. Researcher Matthijs Kox: "The level of cytokines was significantly less elevated in COVID-19 patients than in patients with septic shock and ARDS. Compared to patients with septic shock without ARDS, so without severe pulmonary disease, patients with COVID-19 also displayed markedly lower levels of IL-6 and IL-8. The cytokine concentrations in COVID-19 patients were similar to those in IC patients with trauma or cardiac arrest, conditions that are not noted for a cytokine storm."
The results from this study show that COVID-19 is not characterized by a cytokine storm. Professor of Intensive Care Medicine Peter Pickkers: "The severe disease observed in critically ill COVID-19 patients is therefore not explained by strongly elevated levels of inflammatory proteins in the blood. This means that critically ill COVID-19 patients likely will not benefit from specific anti-cytokine therapies."
Publication in JAMA: Cytokine levels in critically ill patients with COVID-19 and other conditions - Matthijs Kox, Nicole J.B. Waalders, Emma J. Kooistra, Jelle Gerretsen, Peter Pickkers
Related news items
New ultra-high field MRI system available for Radboudumc and Radboud University10 June 2021
Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up.read more
On the prevalence of cerebral amyloid angiopathy a systematic review and meta-analysis10 June 2021
Published in ‘Alzheimers and Dementia’, researchers at Radboudumc performed a systematic review and meta-analysis on the prevalence of Cerebral Amyloid Angiopathy. They scrutinized and analyzed 170 publications, comprising publications using either a neuroimaging or a neuropathological approach.read more
Retina-on-chip modeling and treating eye diseases in a dish10 June 2021
Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.read more
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses8 June 2021
Jeroen Creemers and Johannes Textor published in the Journal for ImmunoTherapy of Cancer that a tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.read more
New method to prevent ovarian cancer increases quality of life8 June 2021
Researchers at Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after fallopian tube removal with delayed ovarian removal to prevent ovarian cancer.read more